Business Context and Reporting Period
This Form 8-K filing by IRADIMED CORP (IRMD) was submitted on November 5, 2019, with the report date of November 6, 2019. The filing addresses a corporate governance event under Item 8.01 (Other Events) regarding the establishment of a new insider trading plan for a senior executive.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of an executive trading plan and contains no financial performance data.
Material Changes
The material change disclosed is the termination of a previous stock trading plan and the adoption of a new one by Brent Johnson, Executive Vice President of Worldwide Sales and Marketing. The new plan was entered into on November 5, 2019, replacing the plan established on May 15, 2019.
Guidance, Outlook, and Management Commentary
- New 10b5-1 Plan Details: The new plan allows Mr. Johnson to sell shares daily from November 2019 through May 2020.
- Conditions: Sales are contingent on the market price of the Company's common stock reaching or exceeding specific minimum price thresholds defined in the plan.
- Disclosure: Future transactions executed under this plan will be reported via Form 4 filings.
- Risks and Contingencies: No specific risks or contingencies are detailed in this filing beyond the standard execution of the trading plan.
Investor Verification Checklist
- Verify the specific minimum price thresholds set in the New 10b5-1 Plan, as these are not disclosed in this summary.
- Monitor subsequent Form 4 filings to track actual share sales executed by Brent Johnson under the new plan.
- Confirm the total number of shares authorized for sale under the new plan, as this figure is not explicitly stated in the text.